Definitive high-dose radiotherapy with concurrent chemotherapy for locally advanced rectal cancer: A case report and literature review
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Min-Jeong | - |
dc.contributor.author | Kim, Eun Seok | - |
dc.contributor.author | Yeo, Seung-Gu | - |
dc.date.accessioned | 2021-08-11T16:46:21Z | - |
dc.date.available | 2021-08-11T16:46:21Z | - |
dc.date.issued | 2016-10 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.issn | 1536-5964 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8720 | - |
dc.description.abstract | Background:Standard management for locally advanced rectal cancer (LARC) involves preoperative chemoradiotherapy (CRT) and radical surgery. However, this level of treatment may be unnecessary for a subgroup of LARC patients. Previous reports have shown that approximately 20% of LARC patients experience a complete tumor response to preoperative CRT. Post-CRT nonoperative management of these patients may prevent morbidities associated with radical surgery. To our knowledge, this case report firstly presents the favorable long-term outcomes of a LARC patient who underwent definitive aim CRT.Methods:The patient was 73 years' old, and staging workups revealed T3N2bM0 rectal adenocarcinoma. He agreed to receive CRT, but refused surgery. A radiotherapy (RT) dose of 64.8 Gy was prescribed, which was higher than conventional (50.4 Gy) preoperative aim RT. The regimen of concurrent chemotherapy was the same as that used in preoperative aim CRT: 2 cycles of 5-fluorouracil and leucovorin.Results:Three months after CRT completion, a complete tumor response was identified clinically. Colonoscopic biopsy after 1 year showed no tumor cells. This patient is alive after 4 years with no evidence of recurrence or severe toxicity.Conclusion:The long-term outcomes of this case indicate the feasibility of definitive high-dose RT with concurrent chemotherapy for LARC. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | Definitive high-dose radiotherapy with concurrent chemotherapy for locally advanced rectal cancer: A case report and literature review | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1097/MD.0000000000005059 | - |
dc.identifier.scopusid | 2-s2.0-84995600654 | - |
dc.identifier.wosid | 000386350900056 | - |
dc.identifier.bibliographicCitation | Medicine, v.95, no.40 | - |
dc.citation.title | Medicine | - |
dc.citation.volume | 95 | - |
dc.citation.number | 40 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | TOTAL MESORECTAL EXCISION | - |
dc.subject.keywordPlus | POSTOPERATIVE CHEMORADIOTHERAPY | - |
dc.subject.keywordPlus | PREOPERATIVE RADIOTHERAPY | - |
dc.subject.keywordPlus | NONOPERATIVE MANAGEMENT | - |
dc.subject.keywordPlus | CHEMORADIATION THERAPY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | WAIT | - |
dc.subject.keywordPlus | WATCH | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordAuthor | nonoperative management | - |
dc.subject.keywordAuthor | radiation therapy | - |
dc.subject.keywordAuthor | rectal cancer | - |
dc.subject.keywordAuthor | watch-and-wait | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.